Five (4%) lung adenocarcinomas presented a more heterogeneous EGFR mutational status: three cases with concomitant tyrosine–kinase inhibitor (TKI)‐sensitive deletion in exon 19 and the TKI‐resistant T790M mutation in exon 20, and two cases with simultaneous occurrence of the TKI‐sensitive mutation L858R in exon 21 and the T790M variant. Here, EGFR is linked to lung adenocarcinoma.